.jpg)
"The new name for the Montreal-headquartered company stems from the 2019 combination of contract research organization Caprion Biosciences, which specializes in immunology and proteomics services, and HistoGeneX, a provider of histopathology and genomics services based in Antwerp. Recently, CellCarta further expanded its scientific capabilities and geographic presence through the acquisitions of Nova Scotia-based Clinical Logistics Inc. and California-based Mosaic Laboratories LLC. As a result, CellCarta is well positioned to serve the global clinical trial requirements of its pharmaceutical and bio-tech clients with state-of-the-art facilities in the United States, Canada, Europe and China. CellCarta is backed by Arsenal Capital Partners..."
